Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?
Vnitr Lek
; 67(1): 37-40, 2021.
Article
em En
| MEDLINE
| ID: mdl-33752389
ABSTRACT
Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at the same time. It is better to start therapy before the patient is at high risk of a fatal cardiovascular event. To improve the patients prognosis, it is important not only to achieve the target LDL-cholesterol value and the optimal blood pressure value, but it is also very important (and often more difficult) to maintain the patients good and long-term adherence to established combination pharmacotherapy. For better adherence to long-term therapy also contributes reduction the number of tablets, which can be achieved through the use of a fixed combination of statins and antihypertensive agents.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Dislipidemias
/
Hipertensão
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Vnitr Lek
Ano de publicação:
2021
Tipo de documento:
Article